Clinical Trial Update: REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B Infection [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for REP 2139-Mg and REP 2165-Mg combination therapy in Chronic Hepatitis B has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• REP 2139-Mg (REP 2139-Mg)
• REP 2165-Mg (REP 2165-Mg)

Snippet

Sponsor: Replicor Inc. | Conditions: Chronic Hepatitis B | Phase 2 | Status: COMPLETED